289 results about "Cerebral arterial thrombosis" patented technology

The invention discloses HGG (Human Gammaglobulin) polypeptide in combination with the tissue specificity of cerebral arterial thrombosis. The invention relates to a method for obtaining the polypeptide. The method comprises the following steps: carrying out in-vivo selection of a mouse MCAO (Middle Cerebral Artery Occlusion) cerebral arterial thrombosis model by adopting an in-vivo phage display peptide library screening technology so as to obtain phage clones in combination with cerebral arterial thrombosis tissue; and randomly selecting the plurality of phage clones to sequence, and authenticating the in-vivo combination specificity of HGG peptide and coded phage clones HGG-M13 thereof. The invention further relates to application of the polypeptide in preparation of a high-sensitivity imaging molecular probe and a targeting delivery neuroprotective drug for cerebral stroke. The polypeptide can be synthesized through an artificial method; the polypeptide is low in molecular weight, high in activity and penetrating power, good in specificity and low in toxicity, and has good tissue targeting of cerebral arterial thrombosis in vivo; and therefore, the polypeptide is applicable to serving as a carrier of the high-sensitivity imaging molecular probe and the targeting delivery neuroprotective drug.

The invention discloses the use of an agent for detecting microRNA in exosomes in the preparation of a product for judging the presence and/or degree of cerebral ischemic injury, and relates to a method for early discrimination of a subject suffering from cardiogenic ischemic stroke and non-cardiogenic ischemic stroke. The method uses the exosomes in high-molecular polymer precipitate serum and areal-time fluorescence quantitative PCR technology, and experimental results show that the specificity and sensitivity of miR-155-5p and miR-93-5p are significantly higher than existing protein markers. Meanwhile, miR-133a-3p and miR-208a-3p expression of the exosomes of patients with cardiogenic ischemic stroke is significantly higher compared with patients with non-cardiogenic ischemic stroke under the condition of no significant changes in the serum miR-133a-3p and miR-208a-3p at the early stage so that the agent can be used as a marker to distinguish the cardiogenic ischemic stroke and thenon-cardiogenic ischemic stroke.

The invention discloses a multi-mode nuclear magnetic image cerebral arterial thrombosis lesion segmentation method based on a convolutional neural network. The method comprises the steps of designinga deep convolutional neural network 1 based on an original framework of a 3D U-Net network; basic modules based on a 3 * 3 * 3 convolution layer and a batch standardization layer; a 3D deformable convolution module based on a 3 * 3 * 3 convolution layer and trilinear interpolation; a cascade deformation module based on the 3D deformable convolution module and the basic module; constructing a deepconvolutional neural network 2 based on the 3D U-Net network and the cascaded deformation module; inputting the processed data into a neural network 1 for pre-training; assigning a weight obtained bypre-training to a neural network 2 for training; and verifying the segmentation effect on the test set of the pixel-level label. The invention provides an automatic labeling method for ischemic stroke lesion segmentation, so that the cost of labeling data is greatly reduced, the engineering operability is enhanced to a certain extent, and doctors are assisted in clinical diagnosis of ischemic stroke patients.

The invention discloses a miRNA marker. The miRNA marker is miRNA-4252. Whether a patient suffers from cerebral arterial thrombosis or not can be diagnosed by detecting the expression level of the miRNA-4252. An experiment shows that a cerebral arterial thrombosis patient and a healthy person can be effectively differentiated through the miRNA-4252. On the basis, the miRNA-4252 can be used for preparing a product for diagnosing the cerebral arterial thrombosis. By means of the cerebral-arterial-thrombosis miRNA marker, the sensitivity and the specificity of diagnosing of the cerebral arterial thrombosis can be greatly improved, and early diagnosis of the cerebral arterial thrombosis is achieved.

The invention discloses an application of a photochemically-induced cerebral arterial thrombosis model for zebra fish. The cerebrum tissue is taken as an identification index of cerebral arterial thrombosis model for zebra fish. The principle of forming photochemically-induced thrombus is adopted. A rose-bengal solution is injected to abdominal cavities of zebra fish. Therefore, complete local infarction in cortex areas of zebra fish is caused by illumination within short time. Accordingly, an in vivo animal model is established. In the model, blood coagulation is caused by damaging vascular endothelial cells due to singlet oxygen released by the rose-bengal solution under light irradiation. The pathological process of cerebral arterial thrombosis is effectively simulated. According to anexperiment result of an observational index, the cerebrum area tissue of zebra fish has evident loose and infarct phenomena. Swimming behaviors of dysneuria such as whirling and standing upright occurto zebra fish. The method is simple and high in success rate and convenient to promote. Damage sensitivity of cerebrum tissue is high and repeatability is good. The photochemically-induced cerebral arterial thrombosis model for zebra fish can act as a practical tool index for screening medicine, for blood vessel protection after cerebral infarction and thrombolytic therapy.

The invention relates to the medical field, discloses applications of racemes of pinocembrin, racemes of pinocembrin salt, racemes of pinocembrin precursors or racemes of pinocembrin hydrate in preparation of medicals for preventing and treating cerebral apoplexy, and further discloses the application of racemes of pinocembrin in prevention and treatment of acute ischemic stroke.

The invention discloses aryl substituted piperazine carbonyl derivative as well as a preparation method and application thereof. The aryl substituted piperazine carbonyl derivative is free alkali or salt of a compound adopting a general formula (I) shown in the Specification, wherein the salt is one of hydrochloride, hydrobromide, sulfate, trifluoroacetate, tartrate, lactate or mesylate; Ar independently represents aryl, substituted heterocyclic ring or substituted aryl; R1 independently represents (-O-CH2-) or (-CH=CH-); R2 and R3 can be the same or different, and respectively and independently represents H, halogen, alkyl, halogen substituted alkyl, nitro, amino, nitrile group, hydroxyl, alkoxy, aryl alkoxy, heterocyclic ring alkoxy, aryl, substituted heterocyclic ring or substituted aryl. The aryl substituted piperazine carbonyl derivative can be applied to the preparation of drugs for treating cerebral arterial thrombosis.

The invention discloses IncRNA markers of cerebral arterial thrombosis. The IncRNA markers are LINC00189 and LOC105376014, wherein the expression of the LINC00189 is up-regulated in a patient with cerebral arterial thrombosis, and the expression of the LOC105376014 is down-regulated in the patient with cerebral arterial thrombosis. The IncRNA markers can be used for early diagnosis of cerebral arterial thrombosis and has relatively high sensitivity and specificity.

The invention discloses a compound of a structure shown by a formula I and a pharmaceutically acceptable salt or solvent compound thereof, wherein R1, R2, R3 and R4 are respectively and independently selected from H, F, Cl, Br, CN, CF3, OH, NO2, NH2, substituted or non-substituted C1 to C6 alkyls, substituted or non-substituted C1 to C6 alkoxy, substituted or non-substituted C1 to C6 alkyl acyls or substituted or non-substituted C1 to C6 alkyl amido groups. The invention also discloses a preparation method of the pharmaceutically acceptable salt or solvent compound of the compound of the structure shown by the formula I and application of the compound to the preparation of medicines for preventing and treating cerebral arterial thrombosis. The formula I is shown in the description.

Provided are a substituted aryl oxygen ethylpiperazine derivative, a preparation method of the substituted aryl oxygen ethylpiperazine derivative and application of the substituted aryl oxygen ethylpiperazine derivative. A compound is free alkali or salt with a compound of a structure in a general formula (I), the salt is one of hydrochloride, hydrobromide, sulfate, trifluoroacetic acid salt, tartrate, lactate or mesylate, wherein an Ar independently stands for aryl groups, substituted heterocyclic rings or substituted aryl groups, an R1 and an R2 are same or different, and the R1 and the R2 independently stand for H, halogen, alkyl, halogen substituted alkyl, nitro, amino, nitrile groups, hydroxyl, alkoxy, aralkyl oxygroup, heterocyclic ring alkoxy, aryl group, the substituted heterocyclic rings or the substituted aryl groups respectively. The substituted aryl oxygen ethylpiperazine derivative is applied to preparation of cerebral arterial thrombosis therapeutic drugs.

The invention discloses a cerebral-arterial-thrombosis diagnosis marker. The marker is miRNA-4511. The miRNA-4511 is highly expressed in a cerebral arterial thrombosis patient, and whether a patient suffers from cerebral arterial thrombosis or not or whether a patient has the risk of suffering from the cerebral arterial thrombosis or not can be diagnosed by detecting the expression level of the miRNA-4511. On the basis, the miRNA-4511 can be used for preparing a product for diagnosing the cerebral arterial thrombosis. As the cerebral-arterial-thrombosis diagnosis marker is discovered, the specificity and the sensitivity of diagnosing of the cerebral arterial thrombosis can be improved, and early diagnosis of the disease is achieved.

The invention discloses a medicine for treating ischemic cerebral arterial thrombosis, of which the active component is Z-octadecyl-9-alkenyl-propylsulfamide being 80-250 mg/kg in effective dose. The medicine is used in an oral manner. The active component of the medicine is the Z-octadecyl-9-alkenyl-propylsulfamide so that the medicine has a significant effect of treating the ischemic cerebral arterial thrombosis, can improve neurological deficit of mice, can reduce cerebral infarction volume and can alleviate the degree of encephaledema.

The invention belongs to the technical field of stem cells and particularly relates to umbilical cord mesenchymal stem cells modified by NTF4 (neurotrophin 4) gene and a construction method and application thereof. The umbilical cord mesenchymal stem cells modified by NTF4 gene are provided herein and can overexpress NTF4 protein. The umbilical cord mesenchymal stem cells modified by NTF4 gene canreplace damaged nerve cells, can well express NTF4 protein to arrive at nerve cell protection and promote cell regeneration and restoration, can be a treatment carrier having great potential of targeting therapy for cerebral arterial thrombosis, and can gain enhanced action of hUC-MSCs so that powerful combination is achieved. Experimental results show that the umbilical cord mesenchymal stem cells modified by NTF4 gene can be applied to model rats with focal cerebral ischemia to effectively repair brain damage of the rats.

The invention discloses a novel pyridine methylamino phthalide compound (I) and pharmaceutically acceptable salts, a preparation method and a pharmaceutical composition thereof and application thereofin preparation of medicines for treating and/or preventing nervous system related diseases. The diseases include but are not limited to vascular dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, HIV related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, glaucoma, cerebral arterial thrombosis, cerebral hemorrhagic stroke, nerve injury causedby cerebral trauma and the like.

The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for cerebral arterial thrombosis. The composition is prepared from the following raw materials in parts by weight: 30 parts of rhodiola rosea, 30 parts of angelica sinensis, 25 parts of acanthopanax root, 25 parts of sculellaria barbata, 25 parts of semen cassiae, 23 parts of semen raphani, 20 parts of lumbricus, 20 parts of gynostemma pentaphylla, 20 parts of radices trichosanthis, 20 parts of ligusticum wallichii, 17 parts of rhizoma acori graminei, 17 parts of caulis spatholobi, 15 parts of astragalus membranaceus, 15 parts of folia perillae acutae, 15 parts of radix curcumae, 12 parts of radix aucklandiae, 10 parts of mulberry, 10 parts of herba epimedii, 10 parts of semen plantaginis, 9 parts of hiraute shiny bugleweed herb, 7 parts of cistanche deserticola, 5 parts of nux vomica and 5 parts of radix aconiti preparata, wherein the raw materials are combined and complemented with each other. The composition has a rapid effect on the cerebral arterial thrombosis, thereby being wide in application prospect.

The invention discloses a class of novel salicylamide compounds (I) and a pharmaceutically acceptable salt thereof, a preparation method and a pharmaceutical composition thereof, and applications of the novel salicylamide compounds (I) and the pharmaceutically acceptable salt thereof in preparation of drugs for treating and/or preventing nervous system related diseases, wherein the diseases include but are not limited to vascular dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, HIV related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, glaucoma, cerebral arterial thrombosis, cerebral hemorrhagic stroke, nerve injury caused by cerebral trauma and the like.